Five Parallel Compliance Lines for Medical Devices in Mexico

1. Key takeaways

Compliance in Mexico is not a single line but five parallel lines: ① the product’s sanitary registration remains valid; ② the batch-by-batch import permit (or the port declaration under Annex II); ③ labels and instructions for use comply with NOM-137 and match the registration dossier; ④ the tecnovigilancia unit operates and reports within the three-tier deadlines; and ⑤ changes and renewals are filed on time. If any one of the five breaks, a gap appears in the legal status of the product, and the gap is rarely confined to the line that caused it. Reading compliance as five lines rather than one checklist is what keeps the structure auditable: each line has its own source, its own deadline logic, and its own owner, and the five must be reconciled rather than each handled in isolation.

• The five lines are registration, import, labelling, vigilance, and change and renewal management.
• Four of the five lines face the holder; the import declaration is filed by the holder or a registration-listed distributor.
• The five cycles run on different clocks and need a single combined calendar.
• Labelling concentrates a heavy workload around 2027-05-14 and pulls registration changes with it.
• Vigilance is the line whose failure stays invisible until an event occurs.

2. Legal basis

Each line draws on its own instruments, and the deadlines differ from line to line, so the table below is the fastest way to see the whole structure at once. Note that the publication dates cited in the first two rows are amendment decrees that changed the underlying provisions, so the dates in force should be confirmed before they are cited in a procedure. The sources and key points are as follows.

3. Expert insights

Insight one: the responsible parties differ across the five lines. For registration, labelling, vigilance, and change and renewal, the external-facing party is the holder; for import, the declarant is the holder or a distributor listed in the registration. Pushing all five lines onto the channel partner magnifies the hold-up risk at the same time, because the partner then controls every element of the product’s legal status. The safer allocation keeps the four holder-facing lines under the holder’s direct control and limits the distributor’s role to the import declaration the rules actually assign to it.

Insight two: the cycles of the five lines are not synchronised. Registration runs on 5 years, import runs batch by batch, label replacement is anchored to 2027-05-14, vigilance is triggered by events, and changes are triggered by product iterations. A single combined calendar manages this better than five separate ledgers, because cross-line conflicts only become visible when the dates sit on one page. The calendar should also show dependencies, since a late registration change can invalidate an otherwise complete label schedule.

Insight three: the labelling line delivers a concentrated shock in 2027. NOM-137-SSA1-2025 adds multiple mandatory content items and requires full consistency with the registration dossier, which means a label revision pulls a registration change along with it. This is the single most concentrated workload of the next two years, and companies that start late will compress both projects into an impossible window. Sequencing the artwork work, the dossier update, and the change filing as one programme is the only way to keep the dates coherent.

Insight four: failure of the vigilance line is the most hidden. Registration expiry has date reminders and import has batch ledgers, but vigilance failure only surfaces when an event occurs. Drills and internal timeliness indicators make this line visible, and they should be scheduled with the same seriousness as the batch ledger checks. A vigilance programme that has never been exercised cannot be trusted to meet a 2-working-day clock on the first real event.

Insight five: Annex II products are simplified on line ② but not on lines ③ and ④. Products exempt from registration and from the import permit must still comply with GMP and with tecnovigilance, and labelling requirements do not disappear because registration is waived; products in the health supplies category must still be compliant. The exemption is a simplification of two lines, never a general exemption, and evidence of the remaining obligations should travel with the goods.

4. Practical recommendations

• Draw a five-line compliance calendar that places the 5-year / 10-year cycle, the batch cycle, 2027-05-14, event triggers, and iteration triggers on one page, and review it at fixed intervals rather than only when a deadline approaches.
• Assign one responsible owner to each of the five lines, all consolidated into the holder’s compliance ledger.
• Run the label replacement as a project, scheduled in coordination with the registration change.
• Test the vigilance line with quarterly drills and internal timeliness indicators (buffers).
• Maintain a GMP and vigilance evidence package for Annex II products, kept available with the goods for inspection.

5. Verification checklist

• □ The five-line compliance calendar has been established
• □ Each of the five lines has a named owner
• □ Label replacement is coordinated with the registration change
• □ The vigilance line has quarterly drills and timeliness indicators
• □ The GMP and vigilance evidence package for Annex II products is ready
• □ Renewal reminders are set for 150 calendar days before expiry

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com